Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 36
Million
400
Region AAMEO at a glance
Diabetes trend in population
Population with diabetes
Diabetes growth rate
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
NN Insulin MS
NN OAD MS
bDKK
24-
NN GLP-1 MS
First nine months of
2018
Sales
(mDKK)
YTD
growth²
80%
88%
Long-acting insulin³
987
27%
GLP-1
Premix insulin4
1,980
11%
346
23.1%1
300
60%
Fast-acting insulin5
1,640
13%
16
Human insulin
1,557
13%
200
360%
4.1%¹
Insulin
40%
Total insulin
6,164
14%
184
GLP-16
662
9%
8
100
- 20%
11.1%1
OAD
Other diabetes care?
Diabetes care
500
(4%)
7,326
12%
40
0
2000
2017
2045
Obesity (SaxendaⓇ)
321
201%
0%
Aug
2013
Biopharm³
1,513
8%
Aug
2018
Total
9,160
14%
AAMEO: Africa, Asia, the Middle-East and Oceania
AAMEO population 2018: ~4.3 billion people and diabetes prevalence
~7.5%
Source: International Diabetes Federation: Diabetes Atlas 1st Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share for insulin as of Aug 2018: Sanofi 32%
and Eli Lilly 12%
Competitor value market share for GLP-1 as of Aug 2018: AstraZeneca
33% and Eli Lilly 23%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Aug, 2018 value figures
2 Percentage change in local currency from YTD Q3 2017 to YTD Q3 2018
3 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 4 Comprises NovoMix®
and RyzodegⓇ; 5 Comprises NovoRapidⓇ; 6 Comprises VictozaⓇ;
7 Comprises Novo NormⓇ and needles; 8 Comprises primarily
NovoSeven®, NovoEight®, NovoThirteen®, NorditropinⓇ, VagifemⓇ and
Activelle®View entire presentation